Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

March 27, 2015 6:00 PM ET


Company Overview of Genetic Immunity, LLC

Company Overview

Genetic Immunity, LLC, a biotechnology company, engages in the development of nano-medicine based therapeutic vaccines against infectious diseases, cancer, allergy, AIDS, and other chronic conditions. Its products include DermaVir, a therapeutic vaccine candidate for the treatment of HIV/AIDS; Intracellular Bacteria, a chlamyderm vaccine against Chlamydia infections; DermAll, a vaccine against dust mite allergen; and DermaPrep, a transdermal delivery system. Genetic Immunity, LLC was founded in 1998 and is based in McLean, Virginia with business, medical, and legal operations in the United States; and research facilities in Hungary and Italy. As of September 28, 2012, Genetic Immunity, LLC o...

8300 Greensboro Drive

Suite 800

McLean, VA 22102

United States

Founded in 1998





Key Executives for Genetic Immunity, LLC

Chief Executive Officer, President and Chief Science Officer
Age: 55
Chief Financial officer and Treasurer
Chief Operating officer and Vice President of Operations
Chief Medical officer
Director of Finance & Administration
Compensation as of Fiscal Year 2014.

Genetic Immunity, LLC Key Developments

Genetic Immunity, LLC Announces Executive Appointments

Julianna Lisziewicz, Ph.D. has been appointed as Chief Science Officer of Genetic Immunity, LLC. In addition, Franco Lori, M.D. will no longer serve as a member of the Board. On May 31, 2013, the Board unanimously approved the appointment of Peter Boros as a member of the Board. Mr. Peter Boros currently serves as Chief Executive Officer of iGlue Inc. where he is responsible for the day to day operations of the company. Since July 1, 2007, Mr. Boros has served as the Commercial Director of Co-Op Inc.

Similar Private Companies By Industry

Company Name Region
Biomedica Inc. United States
Eureka Therapeutics, Inc. United States
Ampla Pharmaceuticals, Inc. United States
Genescient Corporation United States
Syntherica Corp. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Genetic Immunity, LLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at